T

wo former high-ranking pharmaceutical executives are leading a new Cambridge, Mass., biotech that has received $58 million in venture capital to develop treatments for disorders related to the immune system.

Anthony J. Coyle, a former senior vice president at Pfizer (PFE), has been named chief executive, and Jo Viney, a former senior vice president at Biogen (BIIB), will become chief scientific officer of the newly founded Pandion Therapeutics, the company said Thursday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.